Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - TEVA PHARMACEUTICAL INDUSTRIES LTD | d578315dex991.htm |
| 8-K - FORM 8-K - TEVA PHARMACEUTICAL INDUSTRIES LTD | d578315d8k.htm |
Exhibit 99.2
Reclassified selected financial data (unaudited)
| Year ended December 31, |
Three months ended | |||||||||||||||||||||||
| 2017 | 2016 | December 31, | September 30, | June 30, | March 31, | |||||||||||||||||||
| 2017 | ||||||||||||||||||||||||
| (Unaudited, U.S.$ in millions) | ||||||||||||||||||||||||
| Revenues |
$ | 22,385 | $ | 21,903 | $ | 5,398 | $ | 5,617 | $ | 5,720 | $ | 5,650 | ||||||||||||
| Gross profit |
10,825 | 11,859 | 2,481 | 2,650 | 2,855 | 2,839 | ||||||||||||||||||
| Research and development expenses |
1,778 | 2,077 | 346 | 531 | 469 | 432 | ||||||||||||||||||
| Selling and marketing expenses |
3,605 | 3,789 | 860 | 843 | 944 | 958 | ||||||||||||||||||
| General and administrative expenses |
1,451 | 1,390 | 350 | 372 | 363 | 366 | ||||||||||||||||||
| Other asset impairments, restructuring and other items |
5,074 | 1,419 | 3,865 | 550 | 419 | 240 | ||||||||||||||||||
| Legal settlements and loss contingencies |
500 | 899 | 176 | (20 | ) | 324 | 20 | |||||||||||||||||
| Other income |
(1,199 | ) | (769 | ) | (1,099 | ) | (4 | ) | (24 | ) | (72 | ) | ||||||||||||
| Goodwill impairment charge |
17,100 | 900 | 11,000 | — | 6,100 | — | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Operating Income (loss) |
$ | (17,484 | ) | $ | 2,154 | $ | (13,017 | ) | $ | 378 | $ | (5,740 | ) | $ | 895 | |||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||